Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve Provider Recommendation and HPV Vaccination Rates Among Latino/a Adolescents
Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER, HOUSTON · Sep 13, 2024
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to improve the rates of Human Papillomavirus (HPV) vaccinations among Latino/a adolescents by working with healthcare providers at specific community health centers. The study aims to understand how different strategies to support healthcare practices can help doctors recommend the HPV vaccine more effectively and boost vaccination rates. Researchers will be testing these strategies at nine health centers that primarily serve Latino/a families and have lower vaccination rates.
To participate, the health centers must have less than 60% of their eligible 11-12 year old patients starting the HPV vaccine series and a patient population that is at least half Latino. Healthcare providers and staff members at these centers, as well as parents of adolescents aged 11-17 who seek care there, may be eligible to join the study. Participants can expect to receive training and support to help them improve vaccine recommendations and will be involved in measuring the impact of these new strategies. This trial is a great opportunity for healthcare staff and families to play a role in improving adolescent health in their communities.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • FQHC's with less than 60% HPV vaccine initiation rate for 11-12 year old adolescents overall at their practice sites
- • FQHC's that have family medicine and/or pediatric practices
- • a total adolescent patient population at least 50% Latino
- • be willing for Health Care Provider (HCP) and staff members to receive education, training, and support; complete standardized measurement, and agree to randomization.
- • Providers, aged 18 and over, employed at each FQHC (4 staff per practice)
- • Staff, aged 18 and over, employed at each FQHC (5 staff per practice)
- • Implementation team members (i.e., administrative designee, health care providers, immunization navigators, and other staff), aged 18 and over, employed at each FQHC (4 members per practice)
- • Parents (aged 18 and over) of patients ages 11-17 seeking care at each FQHC (25 per practice).
- Exclusion Criteria:
- • -FQHCs that participated in the pilot study were excluded.
About The University Of Texas Health Science Center, Houston
The University of Texas Health Science Center at Houston (UTHealth) is a leading academic institution dedicated to advancing health through education, research, and clinical practice. As a prominent sponsor of clinical trials, UTHealth leverages its extensive resources and expertise in biomedical research to facilitate innovative studies aimed at improving patient outcomes. The institution is committed to fostering a collaborative environment that promotes scientific discovery and the translation of research findings into effective healthcare solutions, all while adhering to the highest ethical standards and regulatory guidelines. With a multidisciplinary approach, UTHealth plays a critical role in addressing complex health challenges and enhancing the quality of life in diverse communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Daisy Y Morales Campos, PhD
Principal Investigator
The University of Texas Health Science Center, Houston
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported